Albendazole (ABZ) is a sulfanyl-benzimidazole anthelmintic drug used worldwide in the treatment and prevention of parasitic diseases in animals and humans. Following oral administration, ABZ is rapidly oxidized into the pharmacologically active chiral sulfoxide metabolite known as ricobendazole (RBZ). As its achiral precursor, RBZ shows very low intestinal absorption due to its poor solubility in water (0.06 mg mL−1). To the best of our knowledge, there is no known example in human medicine of a water-soluble salt form of racemic or enantiomerically pure RBZ. In the present study, we describe in detail the preparation of the sodium (Na) salt of the enantiomers of RBZ through a two-step process: i) the multi-milligram resolution of RBZ by HPLC on the amylose-based Chiralpak IG chiral stationary phase under polar organic mode; ii) the salification of the isolated enantiomers of RBZ by reaction with sodium hydroxide solution. The spectroscopic and chiroptical properties of the RBZ-Na enantiomers were determined. Due to their unique solubility in 0.01 M phosphate buffer at physiological pH (14.49 mg mL−1) and the high sample throughput obtained on semipreparative separation of the non-salified form, it is potentially possible to develop new anthelmintic enantiopure formulations with improved pharmacokinetic properties and lower toxicity.

The sodium salt of the enantiomers of ricobendazole: preparation, solubility and chiroptical properties / Cirilli, Roberto; Guglielmi, Paolo; Formica, Francesca Romana; Casulli, Adriano; Carradori, Simone. - In: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. - ISSN 0731-7085. - 139:(2017), pp. 1-7. [10.1016/j.jpba.2017.01.057]

The sodium salt of the enantiomers of ricobendazole: preparation, solubility and chiroptical properties

Guglielmi, Paolo;
2017

Abstract

Albendazole (ABZ) is a sulfanyl-benzimidazole anthelmintic drug used worldwide in the treatment and prevention of parasitic diseases in animals and humans. Following oral administration, ABZ is rapidly oxidized into the pharmacologically active chiral sulfoxide metabolite known as ricobendazole (RBZ). As its achiral precursor, RBZ shows very low intestinal absorption due to its poor solubility in water (0.06 mg mL−1). To the best of our knowledge, there is no known example in human medicine of a water-soluble salt form of racemic or enantiomerically pure RBZ. In the present study, we describe in detail the preparation of the sodium (Na) salt of the enantiomers of RBZ through a two-step process: i) the multi-milligram resolution of RBZ by HPLC on the amylose-based Chiralpak IG chiral stationary phase under polar organic mode; ii) the salification of the isolated enantiomers of RBZ by reaction with sodium hydroxide solution. The spectroscopic and chiroptical properties of the RBZ-Na enantiomers were determined. Due to their unique solubility in 0.01 M phosphate buffer at physiological pH (14.49 mg mL−1) and the high sample throughput obtained on semipreparative separation of the non-salified form, it is potentially possible to develop new anthelmintic enantiopure formulations with improved pharmacokinetic properties and lower toxicity.
2017
chiralpak ig; enantiomers; neglected tropical diseases; ricobendazole sodium salt; semipreparative resolution; water solubility; albendazole; chemistry, pharmaceutical; chromatography, high pressure liquid; sodium; solubility; stereoisomerism; analytical chemistry; 3003; drug discovery3003 pharmaceutical science; spectroscopy; clinical biochemistry
01 Pubblicazione su rivista::01a Articolo in rivista
The sodium salt of the enantiomers of ricobendazole: preparation, solubility and chiroptical properties / Cirilli, Roberto; Guglielmi, Paolo; Formica, Francesca Romana; Casulli, Adriano; Carradori, Simone. - In: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. - ISSN 0731-7085. - 139:(2017), pp. 1-7. [10.1016/j.jpba.2017.01.057]
File allegati a questo prodotto
File Dimensione Formato  
Cirilli_Sodium_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1194466
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 24
social impact